New name, but same old problems for Posimir as FDA hits Durect again

Ben Adams Durect may have changed the name of its post-pain gall bladder surgery drug from "Posidur" to "Posimir" this year, but this has not stopped its run of ...

Just wait, Perrigo investor urges. We can get the same return–without a Mylan deal

Carly Helfand All eyes are on Perrigo's investors, who will have to decide whether to accept Mylan's offer when the wannabe acquirer takes it to them next Monday. And Israeli ...

Bloomberg: Sun plant banned by FDA had same issues faced by Ranbaxy

Eric Palmer Sun Pharmaceutical's $ 3.2 billion buyout offer for Ranbaxy Laboratories also came with a pledge to clean up the act of India's largest generic drugmaker, which ...
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS